Thus, aberrant CSF1 signaling plays a critical role in tumor development and progression in PVNS/TGCT, which may therefore represent the ideal index disease to test the therapeutic value of CSF1 inhibitors. Here, CSF1 is linked to tenosynovial giant cell tumor, diffuse type.